Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CS44 | ISIN: US61225M1027 | Ticker-Symbol:
NASDAQ
28.03.24
20:28 Uhr
7,070 US-Dollar
+0,090
+1,29 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MONTE ROSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MONTE ROSA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MONTE ROSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.03.Monte Rosa Therapeutics GAAP EPS of -$0.581
14.03.Monte Rosa Therapeutics: Q4 Earnings Insights1
14.03.Monte Rosa Therapeutics, Inc. - 10-K, Annual Report-
14.03.Monte Rosa Therapeutics, Inc. - 8-K, Current Report1
14.03.Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update471MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose...
► Artikel lesen
11.03.Monte Rosa Therapeutics announces NEK7 inhibitor for inflammation1
11.03.Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor445MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1ß and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable...
► Artikel lesen
15.02.Monte Rosa draws bullish view at Wedbush on protein degradation1
15.02.Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst1
31.01.Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences1
08.01.Monte Rosa Therapeutics, Inc. - 8-K, Current Report2
08.01.Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024139Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously...
► Artikel lesen
09.11.23Monte Rosa Therapeutics GAAP EPS of -$0.703
09.11.23Adaptimmune, Monte Rosa and Intellia discontinue programs28
09.11.23Monte Rosa Therapeutics, Inc. - 8-K, Current Report1
09.11.23Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update134Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration...
► Artikel lesen
07.11.23Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases1
27.10.23Monte Rosa Therapeutics Shares Rebound After Investment Boost1
27.10.23Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences1
26.10.23Monte Rosa Therapeutics prices offering to raise $25M2
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1